-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Following Shanghai, Wuxi, Yangzhou, Tianjin, Hangzhou and other places, Beijing has recently fully carried out the appointment and vaccination of CanSino Biologics inhaled recombinant new coronavirus vaccine
.
The relevant person in charge of CanSino Biologics Co.
, Ltd.
said in an interview with China News Agency in Beijing a few days ago that the inhaled vaccine will gradually cover more provinces and cities in the future, and is currently organizing personnel to train medical staff at internal and provincial vaccination sites on the operation of
the instrument 。
Inhaled vaccine dose: only one-fifth of intramuscular injection
On the basis of not changing the composition of the vaccine, CanSino Biologics innovated the delivery method, atomized the vaccine into tiny droplets, and launched the world's first "oral inhalation" vaccination of the new crown vaccine, simulating the process of virus invasion of the human body and wearing an "invisible mask"
for the respiratory system.
Liu Wei, senior vice president of organization management and human resources of CanSino Biologics, told reporters that the formulation formula of the new crown vaccine for inhalation and intramuscular injection is the same
.
CanSino Biologics has developed the new crown vaccine Keweisha for inhalation on the basis of the intramuscular adenovirus vector new crown vaccine Kewesha, which is completed by oral inhalation, and the inhalation dose is only one-fifth
of the intramuscular injection dose.
Liu Wei said that the use of inhalation administration, on the one hand, the respiratory mucosa area is very large, through inhalation administration to increase the area of human immune response, can better produce the expression of antigens, enhance the effect
of vaccines.
On the other hand, inhaled vaccines can cause mucosal immunity by touching part of the mucosa, which is expected to block the spread of the virus and prevent infection
.
Vaccines pass world-class "big test"
On May 19 this year, the World Health Organization (WHO) announced that the recombinant new crown vaccine Kewesha, developed by China's CanSino Biologics Co.
, Ltd.
, officially passed the WHO emergency use certification
.
This is the 11th COVID vaccine
in the world to receive WHO emergency use authorization.
On January 20, 2020, CanSino Biologics officially decided to start the research and development of the new crown vaccine, and in March of the same year, after 55 days of round-the-clock efforts and strict review by relevant departments, CanSino successfully developed the world's first new crown vaccine
that entered the clinical stage.
The new crown vaccine for intramuscular injection of Kewesha was approved for conditional marketing
by the State Food and Drug Administration in only 400 days from the beginning of the project.
For such a speed of research and development, Liu Wei said that CanSino Biologics' new crown vaccine is a vaccine
developed based on the virus vector technology platform.
In the early stage of the new crown vaccine project, based on the existing technical platform, it was considered that the adenovirus vector technology platform was mature, stable, rapid and effective
.
Considering the tight development time, it was decided to use adenovirus vector technology for the development
of the new crown vaccine first.
"CanSino Biologics' technology platform can allow us to start vaccine research and development soon," CanSino Biologics Chairman and CEO Yu Xuefeng said in a previous interview with the media, for example, for the Omicron variant, we only need to understand its mutations and sequences, whether it is using adenovirus vector platforms or mRNA technology platforms, we can quickly start the corresponding work
.
Booster immunization has been carried out in many places
On October 26, Shanghai became the first city
in China to initiate the booster immunization of CanSino Biologics' inhaled recombinant novel coronavirus vaccine (adenovirus type 5 vector).
According to the work deployment of the joint prevention and control mechanism of the State Council, people aged 18 and above who have been fully vaccinated with inactivated vaccine and intramuscular recombinant novel coronavirus vaccine (adenovirus type 5 vector) for 6 months can choose to use inhaled recombinant new coronavirus vaccine (adenovirus type 5 vector) for 1 dose of booster immunization
.
Liu Wei said that after the inhaled new crown vaccine was included in China's emergency use authorization, vaccination has been carried out in Shanghai, Jiangsu, Tianjin, Zhejiang, Beijing and other places since October 2022
.
In the future, inhaled vaccines will gradually cover all provinces, cities and regions across the country, and personnel are also being organized to train medical staff in internal and provincial vaccination sites on the operation of the instrument
.
(End)
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
